12931_2024_2707_MOESM1_ESM.docx (1001.37 kB)
Additional file 1 of Blood MMP-9 measured at 2 years after lung transplantation as a prognostic biomarker of chronic lung allograft dysfunction
journal contribution
posted on 2024-02-10, 04:41 authored by Adrien Tissot, Eugénie Durand, Thomas Goronflot, Benjamin Coiffard, Benjamin Renaud-Picard, Antoine Roux, Xavier Demant, Jean-François Mornex, Loïc Falque, Mathilde Salpin, Jérôme Le Pavec, Thomas Villeneuve, Véronique Boussaud, Christiane Knoop, Antoine Magnan, David Lair, Laureline Berthelot, Richard Danger, Sophie BrouardAdditional file 1: S1. COLT study protocol. S2. Description of variables of interest. Figure S1. Study protocol. Figure S2. Comparison of MMP-9 blood levels of Y2 analysis according to CLAD phenotypes. Figure S3. Precision-Recall (A) and ROC (B) curves for the Y1 MMP-9 analysis. Figure S4. Comparison of MMP-9 blood levels of Y2 analysis according to CLAD phenotypes. Figure S5. Longitudinal analysis of MMP-9 blood levels for recipients with available samples before transplantation, at Y1 and Y2.
Funding
Agence Nationale de la Recherche Institut de Recherche en Santé Respiratoire des Pays de Loire La Fondation du Souffle Le Fonds de Recherche en Santé Respiratoire
History
Usage metrics
Keywords
secretory endopeptidase identifiedmatrix metalloproteinase 9fibrosis processes associatedconclusion plasmatic mmp2 years followinganalysed stable recipients2 yearsyear 2stable groupsstable groupyear 1would developtime pointsterm outcomessignificantly differentresults mmpremain hamperedplasma mmpmultivariate analysismethods participantskey mediatorindependently associateddiscriminating capacityblood mmpaverage increase9 measurements9 measured9 levels9 level66 %.4 ).230 ng160 ng150 ng129 recipients118 ng003 ).
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC